Abeona Therapeutics Inc. (ABEO)
 NASDAQ: ABEO · Real-Time Price · USD
 4.780
 -0.030 (-0.62%)
  Nov 3, 2025, 4:00 PM EST - Market closed
Abeona Therapeutics Revenue
Abeona Therapeutics had revenue of $400.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $400.00K.
Revenue (ttm) 
 $400.00K
Revenue Growth 
 n/a
P/S Ratio 
 612.78
Revenue / Employee 
 $2,941
Employees 
 136
Market Cap 
245.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | - | - | - | 
| Dec 31, 2023 | 3.50M | 2.09M | 147.52% | 
| Dec 31, 2022 | 1.41M | -1.59M | -52.87% | 
| Dec 31, 2021 | 3.00M | -7.00M | -70.00% | 
| Dec 31, 2020 | 10.00M | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
ABEO News
- 21 hours ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
 - 4 days ago - Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel) - GlobeNewsWire
 - 14 days ago - Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs - GlobeNewsWire
 - 21 days ago - Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program - GlobeNewsWire
 - 26 days ago - Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy - GlobeNewsWire
 - 2 months ago - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
 - 2 months ago - Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript - Seeking Alpha
 - 2 months ago - Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn - Seeking Alpha